Low HDL Cholesterol, Metformin Use, and Cancer Risk in Type 2 Diabetes
| Autor: | Gary T.C. Ko, Linda W.L. Yu, Juliana C.N. Chan, Alice P.S. Kong, Ronald C.W. Ma, Risa Ozaki, Chun-Chung Chow, Wing-Yee So, Heung Man Lee, Xilin Yang |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Type 2 diabetes chemistry.chemical_compound Predictive Value of Tests Risk Factors Neoplasms Internal medicine Diabetes mellitus Medical Staff Hospital Internal Medicine medicine Humans Hypoglycemic Agents Epidemiology/Health Services Research Original Research Aged Advanced and Specialized Nursing biology business.industry Cholesterol Cholesterol HDL Absolute risk reduction nutritional and metabolic diseases Cancer AMPK Middle Aged medicine.disease Metformin Endocrinology Diabetes Mellitus Type 2 chemistry biology.protein Hong Kong lipids (amino acids peptides and proteins) Female Apolipoprotein A1 business Follow-Up Studies Signal Transduction medicine.drug |
| Zdroj: | Diabetes Care |
| ISSN: | 1935-5548 0149-5992 |
| Popis: | OBJECTIVE The AMP-activated protein kinase (AMPK) pathway is a master regulator in energy metabolism and may be related to cancer. In type 2 diabetes, low HDL cholesterol predicts cancer, whereas metformin usage is associated with reduced cancer risk. Both metformin and apolipoprotein A1 activate the AMPK signaling pathway. We hypothesize that the anticancer effects of metformin may be particularly evident in type 2 diabetic patients with low HDL cholesterol. RESEARCH DESIGN AND METHODS In a consecutive cohort of 2,658 Chinese type 2 diabetic patients enrolled in the study between 1996 and 2005, who were free of cancer and not using metformin at enrollment or during 2.5 years before enrollment and who were followed until 2005, we measured biological interactions for cancer risk using relative excess risk as a result of interaction (RERI) and attributable proportion (AP) as a result of interaction. A statistically significant RERI >0 or AP >0 indicates biological interaction. RESULTS During 13,808 person-years of follow-up (median 5.51 years), 129 patients developed cancer. HDL cholesterol CONCLUSIONS The anticancer effect of metformin was most evident in type 2 diabetic patients with low HDL cholesterol. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|